COMMUNIQUÉS West-GlobeNewswire

VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
13/05/2025
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon [...]
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
13/05/2025
Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American Society of Clinical [...]
SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury
13/05/2025
Indication Has Been Granted FDA Breakthrough Device Designation for Potential PMA Filing DENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company [...]
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
13/05/2025
Long-term clinical evaluation represents key advancement following successful first-in-human study RUTHERFORD, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a [...]
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025
13/05/2025
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025 EBX-102 was well tolerated and showed multiple positive trends over placebo Findings support progression to a Phase 2b trial Glasgow, Scotland – 13 May [...]
Reflect Scientific Secures Patents for Data Center Cooling with Cryogenic Innovation
13/05/2025
OREM, Utah, May 13, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leader in cryogenic technology, today announced a U.S. Patent for its innovative system to cool computer rooms using cryogenic [...]
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
13/05/2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies [...]
Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™
13/05/2025
The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in [...]
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
13/05/2025
- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M - - Promising early signal in Cohort P with [...]
Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials
13/05/2025
Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investors Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in [...]
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
13/05/2025
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
Protara Therapeutics to Participate in Upcoming Investor Conferences
13/05/2025
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
13/05/2025
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 million Over 6,000 patients treated to date Initiated CARVYKTI ® clinical production at the Tech Lane facility Received positive [...]
Microbix & Aurevia Introduce Novel EQA Scheme
13/05/2025
Pilot Program for Qualifying Clinical Labs to Diagnose Bacterial Vaginosis MISSISSAUGA, Ontario and HELSINKI, Finland, May 13, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a [...]
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
13/05/2025
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) [...]
Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
13/05/2025
First Clinic Targeted to Open Q4, 2025 in the U.S. VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a [...]
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
13/05/2025
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small [...]
GenVivo Highlights GEN2 Phase 1 Data and GEN-1013 Preclinical Data at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
13/05/2025
GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and expansion trial. GEN-1013 was studied in aggressive murine cancer models using both IV and IT [...]
Immatics Announces First Quarter 2025 Financial Results and Business Update
13/05/2025
IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026 IMA203 PRAME Cell Therapy: Phase 1b clinical trial [...]

Pages